TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
EBS

Emergent Biosolutions Inc

Healthcare · Drug Manufacturers - Specialty & Generic

6.80$ +0.3% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Emergent Biosolutions Inc (EBS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 234 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement EBS
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
271 277 300 255 294 195 222 141 231 149 156 234 770
178 107 160 320 130 58 106 83 102 102 89 97 390
92 169 141 -66 164 137 117 58 129 47 68 137 381
15 29 15 33 14 9.1 15 13 14 12 11 9.2 45
86 90 85 86 77 61 52 44 39 51 47 45 181
335 213 101 138 100 146 68 57 52 63 57 262 435
-242 -44 40 -204 65 -9.5 49 0.5 77 -17 11 -125 -54
20 22 24 24 8.3 15 15 15 15 15 11 10 51
-266 -55 12 -270 142 -28 93 -17 58 -51 13 -166 -146
-2.5 -5.0 3.1 13 28 3.7 25 -4.8 6.4 3.9 6.6 14 31
-263 -50 9.0 -283 115 -31 68 -12 51 -55 6.8 -180 -177
23 -14 63 -132 98 21 133 22 97 -13 49 -156 -24

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?